Eupraxia Pharmaceuticals Inc
TSX:EPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
CA |
|
J
|
Jiangsu Changshu Automotive Trim Group Co Ltd
SSE:603035
|
CN |
|
Eltel AB
STO:ELTEL
|
SE |
|
Surgery Partners Inc
NASDAQ:SGRY
|
US |
|
Garibaldi Resources Corp
XTSX:GGI
|
CA |
|
Ourgame International Holdings Ltd
HKEX:6899
|
CN |
|
CSG Systems International Inc
NASDAQ:CSGS
|
US |
|
Anant Raj Ltd
NSE:ANANTRAJ
|
IN |
|
M
|
MST Golf Group Bhd
KLSE:MSTGOLF
|
MY |
|
Digital China Holdings Ltd
HKEX:861
|
HK |
|
Nexteer Automotive Group Ltd
HKEX:1316
|
US |
|
G
|
Grand Baoxin Auto Group Ltd
HKEX:1293
|
CN |
|
Ansal Properties and Infrastructure Ltd
NSE:ANSALAPI
|
IN |
|
nCino OpCo, Inc.
NASDAQ:NCNO
|
US |
|
C
|
Chalkis Health Industry Co Ltd
SZSE:000972
|
CN |
Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
